Atypical femur fracture in two patients treated with denosumab: case reports of a patient undergoing maintenance hemodialysis and a kidney transplant recipient, with a literature review of the denosumab used to treat these patients

Abstract Background Osteoporosis is a serious complication for both patients undergoing maintenance hemodialysis (MHD) and kidney transplant (KTx) recipients. Denosumab (Dmab) is a highly efficacious drug used to treat osteoporosis. However, like bisphosphonates, Dmab has the rare complication of at...

Full description

Saved in:
Bibliographic Details
Main Authors: Ryoichi Miyazaki, Kyoko Miyagi, Sun Hirayama, Tatsuto Miyanaga
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Renal Replacement Therapy
Subjects:
Online Access:https://doi.org/10.1186/s41100-024-00592-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850254100091895808
author Ryoichi Miyazaki
Kyoko Miyagi
Sun Hirayama
Tatsuto Miyanaga
author_facet Ryoichi Miyazaki
Kyoko Miyagi
Sun Hirayama
Tatsuto Miyanaga
author_sort Ryoichi Miyazaki
collection DOAJ
description Abstract Background Osteoporosis is a serious complication for both patients undergoing maintenance hemodialysis (MHD) and kidney transplant (KTx) recipients. Denosumab (Dmab) is a highly efficacious drug used to treat osteoporosis. However, like bisphosphonates, Dmab has the rare complication of atypical femur fracture (AFF). Here, we report two cases of AFF in a patient on MHD and a KTx recipient during treatment with Dmab. Case presentation Case 1 was a 78-year-old female patient undergoing MHD diagnosed with an AFF in April 2023. In 2018, she started hemodialysis necessitated by glomerulonephritis caused by parvovirus B19. She had been receiving intravenous alendronate for osteoporosis since 2005, then changed to subcutaneous Dmab in 2020. She underwent an intramedullary nail osteosynthesis for her AFF and is doing well on teriparatide. Case 2 was a 67-year-old female KTx recipient diagnosed with an AFF in June 2023. She had been on oral minodronate since 2014 but was switched to subcutaneous Dmab in 2020 owing to repeated fractures. She is doing well on romosozumab after intramedullary nail osteosynthesis. Conclusions We report two cases of AFF treated with Dmab. Case 1 was a patient undergoing MHD and case 2 was a KTx recipient. AFFs are relatively rare and, to our knowledge, have not been reported in patients undergoing MHD or KTx recipients. Dmab-associated AFFs are likely to increase in the future as the population ages, and adequate attention should be paid to patients undergoing MHD and KTx recipients.
format Article
id doaj-art-dc6381f82d9f4c478d14aadb97adbe18
institution OA Journals
issn 2059-1381
language English
publishDate 2024-12-01
publisher BMC
record_format Article
series Renal Replacement Therapy
spelling doaj-art-dc6381f82d9f4c478d14aadb97adbe182025-08-20T01:57:12ZengBMCRenal Replacement Therapy2059-13812024-12-011011710.1186/s41100-024-00592-6Atypical femur fracture in two patients treated with denosumab: case reports of a patient undergoing maintenance hemodialysis and a kidney transplant recipient, with a literature review of the denosumab used to treat these patientsRyoichi Miyazaki0Kyoko Miyagi1Sun Hirayama2Tatsuto Miyanaga3Department of Internal Medicine, Fujita Memorial HospitalDepartment of Internal Medicine, Fujita Memorial HospitalDepartment of Internal Medicine, Fujita Memorial HospitalDepartment of Internal Medicine, Fujita Memorial HospitalAbstract Background Osteoporosis is a serious complication for both patients undergoing maintenance hemodialysis (MHD) and kidney transplant (KTx) recipients. Denosumab (Dmab) is a highly efficacious drug used to treat osteoporosis. However, like bisphosphonates, Dmab has the rare complication of atypical femur fracture (AFF). Here, we report two cases of AFF in a patient on MHD and a KTx recipient during treatment with Dmab. Case presentation Case 1 was a 78-year-old female patient undergoing MHD diagnosed with an AFF in April 2023. In 2018, she started hemodialysis necessitated by glomerulonephritis caused by parvovirus B19. She had been receiving intravenous alendronate for osteoporosis since 2005, then changed to subcutaneous Dmab in 2020. She underwent an intramedullary nail osteosynthesis for her AFF and is doing well on teriparatide. Case 2 was a 67-year-old female KTx recipient diagnosed with an AFF in June 2023. She had been on oral minodronate since 2014 but was switched to subcutaneous Dmab in 2020 owing to repeated fractures. She is doing well on romosozumab after intramedullary nail osteosynthesis. Conclusions We report two cases of AFF treated with Dmab. Case 1 was a patient undergoing MHD and case 2 was a KTx recipient. AFFs are relatively rare and, to our knowledge, have not been reported in patients undergoing MHD or KTx recipients. Dmab-associated AFFs are likely to increase in the future as the population ages, and adequate attention should be paid to patients undergoing MHD and KTx recipients.https://doi.org/10.1186/s41100-024-00592-6Atypical femoral fracturesDemosumabMaintenance hemodialysis patientKidney transplant recipient
spellingShingle Ryoichi Miyazaki
Kyoko Miyagi
Sun Hirayama
Tatsuto Miyanaga
Atypical femur fracture in two patients treated with denosumab: case reports of a patient undergoing maintenance hemodialysis and a kidney transplant recipient, with a literature review of the denosumab used to treat these patients
Renal Replacement Therapy
Atypical femoral fractures
Demosumab
Maintenance hemodialysis patient
Kidney transplant recipient
title Atypical femur fracture in two patients treated with denosumab: case reports of a patient undergoing maintenance hemodialysis and a kidney transplant recipient, with a literature review of the denosumab used to treat these patients
title_full Atypical femur fracture in two patients treated with denosumab: case reports of a patient undergoing maintenance hemodialysis and a kidney transplant recipient, with a literature review of the denosumab used to treat these patients
title_fullStr Atypical femur fracture in two patients treated with denosumab: case reports of a patient undergoing maintenance hemodialysis and a kidney transplant recipient, with a literature review of the denosumab used to treat these patients
title_full_unstemmed Atypical femur fracture in two patients treated with denosumab: case reports of a patient undergoing maintenance hemodialysis and a kidney transplant recipient, with a literature review of the denosumab used to treat these patients
title_short Atypical femur fracture in two patients treated with denosumab: case reports of a patient undergoing maintenance hemodialysis and a kidney transplant recipient, with a literature review of the denosumab used to treat these patients
title_sort atypical femur fracture in two patients treated with denosumab case reports of a patient undergoing maintenance hemodialysis and a kidney transplant recipient with a literature review of the denosumab used to treat these patients
topic Atypical femoral fractures
Demosumab
Maintenance hemodialysis patient
Kidney transplant recipient
url https://doi.org/10.1186/s41100-024-00592-6
work_keys_str_mv AT ryoichimiyazaki atypicalfemurfractureintwopatientstreatedwithdenosumabcasereportsofapatientundergoingmaintenancehemodialysisandakidneytransplantrecipientwithaliteraturereviewofthedenosumabusedtotreatthesepatients
AT kyokomiyagi atypicalfemurfractureintwopatientstreatedwithdenosumabcasereportsofapatientundergoingmaintenancehemodialysisandakidneytransplantrecipientwithaliteraturereviewofthedenosumabusedtotreatthesepatients
AT sunhirayama atypicalfemurfractureintwopatientstreatedwithdenosumabcasereportsofapatientundergoingmaintenancehemodialysisandakidneytransplantrecipientwithaliteraturereviewofthedenosumabusedtotreatthesepatients
AT tatsutomiyanaga atypicalfemurfractureintwopatientstreatedwithdenosumabcasereportsofapatientundergoingmaintenancehemodialysisandakidneytransplantrecipientwithaliteraturereviewofthedenosumabusedtotreatthesepatients